Gemcitabine pulmonary toxicity : CT featuresBOISELLE, Phillip M; MORRIN, Martina M; HUBERMAN, Mark S et al.Journal of computer assisted tomography. 2000, Vol 24, Num 6, pp 977-980, issn 0363-8715Article

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersCOSTA, Daniel B; KOBAYASHI, Susumu; TENEN, Daniel G et al.Lung cancer. 2007, Vol 58, Num 1, pp 95-103, issn 0169-5002, 9 p.Article

Uncommon presentations of some common malignancies: Case 1: Sequential paraneoplastic endocrine syndromes in small-cell lung cancerMAYER, Stephen; CYPESS, Aaron M; KOCHER, Olivier N et al.Journal of clinical oncology. 2005, Vol 23, Num 6, pp 1312-1314, issn 0732-183X, 3 p.Article

Subdivision of the T1 Size Descriptor for Stage I Non-small Cell Lung Cancer Has Prognostic Value: A Single Institution ExperienceCHAO YE; MASTERMAN, Justin R; HUBERMAN, Mark S et al.Chest (American College of Chest Physicians). 2009, Vol 136, Num 3, pp 710-715, issn 0012-3692, 6 p.Article

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancerVANDERLAAN, Paul A; YAMAGUCHI, Norihiro; COSTA, Daniel B et al.Lung cancer. 2014, Vol 84, Num 1, pp 39-44, issn 0169-5002, 6 p.Article

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practiceYAMAGUCHI, Norihiro; VANDERLAAN, Paul A; HUBERMAN, Mark S et al.Lung cancer. 2013, Vol 82, Num 1, pp 31-37, issn 0169-5002, 7 p.Article

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to GefitinibCOSTA, Daniel B; NGUYEN, Kim-Son H; HUBERMAN, Mark S et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 7060-7067, issn 1078-0432, 8 p.Article